ImStar Therapeutics Inc. logo

ImStar Therapeutics Inc.

Developing promising new treatments for Amyotrophic Lateral Sclerosis (ALS) and neurodegenerative diseases ImStar Therapeutics is a pharma company, developing therapeutics directed against a new target, TANA (TDP-43 Associated NF-kB Activation), for the treatment of neurological condition and other related neurodegenerative disorders.

The company came into existence with an idea of encasing the innovation of its co-founder Dr. Jean-Pierre Julien who by investing his efforts found out the lead drug of the company IMS-088 for target TANA.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.imstartx.com
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1285 West Broadway, Suite 600 BC V6H 3X8
Vancouver
Canada
Email
Contact Number

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/imstar-therapeutics-inc-” connections=”true” suffix=””]

In June 2016, ImStar Therapeutics Inc has raised $1.8 million in seed financing, led by Accel-Rx, BDC Capital and AviTx for the development of preclinical work to treat ALS (amyotrophic lateral sclerosis) before moving on to clinic trials.